Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) EBITDA Margin (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed EBITDA Margin for 9 consecutive years, with 2240.9% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin changed N/A year-over-year to 2240.9%; the TTM value through Mar 2026 reached 476697.06%, changed N/A, while the annual FY2025 figure was 1419.61%, N/A changed from the prior year.
  • EBITDA Margin hit 2240.9% in Q1 2026 for Crescent Biopharma, down from 2030.75% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 2030.75% in Q2 2025 and bottomed at 17804.21% in Q2 2022.
  • Average EBITDA Margin over 3 years is 6004.79%, with a median of 2240.9% recorded in 2026.
  • On a YoY basis, EBITDA Margin climbed as much as 1012619720bps in 2022 and fell as far as 1012619720bps in 2022.
  • Crescent Biopharma's EBITDA Margin stood at 17804.21% in 2022, then surged by 111bps to 2030.75% in 2025, then crashed by -210bps to 2240.9% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 2240.9%, 2030.75%, and 17804.21% for Q1 2026, Q2 2025, and Q2 2022 respectively.